CS
CABA icon

Credit Suisse’s Cabaletta Bio CABA Stock Holding History

Credit Suisse’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$570K Hold
33,388
– – ﹤0.01% 2580
2023
Q4 		$758K Buy
33,388
+12,542
+60% +$211K ﹤0.01% 2513
2023
Q3 		$317K Buy
+20,846
New +$285K ﹤0.01% 2914

Other funds holding CABA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Credit Suisse's CABA Position: Q1 2024 in Review

Credit Suisse held its Cabaletta Bio (CABA) position steady in Q1 2024 at 33,388 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #2580.

Credit Suisse first reported a position in CABA in Q3 2023 and has held it in 3 quarters since. The position peaked at $758K in Q4 2023. 159 funds tracked by Wall St. Rank hold CABA as of Q1 2024.

  • Credit Suisse held 33,388 shares of Cabaletta Bio worth $570K as of Q1 2024.
  • Credit Suisse left its Cabaletta Bio share count unchanged in Q1 2024.
  • Cabaletta Bio made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2580 holding.
  • Credit Suisse first reported a position in Cabaletta Bio in Q3 2023 and has held it in 3 quarters since.
  • Credit Suisse's Cabaletta Bio position peaked at $758K in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.